Summary: In adults with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD), 24 g/day of dietary fibre for 12 weeks improved glycaemic control and reduced the FIB-4 liver fibrosis marker compared with standard education or a 12 g/day dose, without a significant change in BMI.
PICO Summary
| Element | Detail |
|---|---|
| Population | Adults with type 2 diabetes and MASLD (n=randomised 1:1:1 across three arms). |
| Intervention | 24 g/day dietary fibre (two 12 g cereal packets) for 12 weeks plus standard health education. |
| Comparison | Standard diabetes education alone, and a 12 g/day fibre arm. |
| Outcome | 24 g arm: HbA1c fell more than control (-1.6 ± 0.6 vs -0.6 ± 0.5; P<0.001), with lower FPG at weeks 8 and 12 and significant FIB-4 reduction. No significant BMI change, attributed to added caloric intake from fibre. |
High-fibre cereal in T2DM with MASLD
RCT · T2DM + MASLD · 12 weeks
Over 12 weeks, 24 g/day dietary fibre cut HbA1c by 1.6% versus 0.6% with standard education (P<0.001) and significantly lowered the FIB-4 fibrosis marker, with no change in BMI. The benefit was dose-dependent and the fibrosis endpoint is a short-term surrogate.
Expert Commentary
Fatty liver sits in almost every type 2 diabetes clinic I run, and my advice on it has long felt thin: lose weight, move more, and hope the liver follows. So a trial suggesting that a simple fibre supplement shifts a fibrosis marker naturally catches my attention. I find the result encouraging but I am holding it at arm’s length, because the honest reading is modest and dose-dependent. The 24 g arm beat both the control and the lower dose on HbA1c and on FIB-4, which is biologically plausible given what fibre does to the gut and to postprandial glucose. What stops me overselling it is the endpoint: FIB-4 is a calculated surrogate, not a biopsy or even elastography of hard outcomes, and twelve weeks is far too short to claim anything about fibrosis progression in a disease measured over years. The flat BMI is an interesting honesty signal too, since the benefit clearly was not simply weight loss. Can I use this with my patients? Yes, comfortably, because recommending more dietary fibre is cheap, safe, and broadly beneficial regardless of the liver question. I would just frame it as sensible nutrition rather than a proven antifibrotic.
References
Chen XS, Liu HZ, Huang F, et al. Impact of a high dietary fiber cereal meal intervention on the progression of liver fibrosis in T2DM with MASLD. Front Endocrinol (Lausanne). 2025;16:1623136. doi:10.3389/fendo.2025.1623136